Krystal Biotech (KRYS) Gross Margin (2023 - 2026)

Krystal Biotech has disclosed Gross Margin across 4 years of filings, most recently posting 94.57% for Q1 2026.

• Gross Margin for Q1 2026 came in at 94.57%, up 27.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 94.17% (up 96.0% YoY), and the FY2025 annual result was 94.08%, up 98.0% from the prior year.
• Gross Margin came in at 94.57% for Q1 2026 at Krystal Biotech, up from 93.85% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 97.39% in Q3 2023 to a low of 91.45% in Q2 2024.
• The 4-year median for Gross Margin is 94.3% (2025), against an average of 94.02%.
• Across the five-year window, Gross Margin slumped 537 bps in 2024 and surged 361 bps in 2025, its largest moves.
• Krystal Biotech's Gross Margin stood at 93.19% in 2023, then rose by 1 bps to 94.57% in 2024, then declined by 1 bps to 93.85% in 2025, then gained by 1 bps to 94.57% in 2026.
• The last three Gross Margin figures came in at 94.57% (Q1 2026), 93.85% (Q4 2025), and 95.64% (Q3 2025), per Business Quant data.